10 results
To assess clinical parameters and biomarkers in blood and urine in predicting bacteremia, need for hospital admission, clinical and bacteriologic cure and mortality in patients with fUTI.To determine whether a 7-day duration of antibiotic treatment…
The primary objective is to select one of two platinum strategies to be used in this regimen for use as experimental arm in Phase III. This is a screening feasibility study addressing purely investigational approaches.
To document that 8 weeks treatment with ledipasvir-sofosbuvir is effective in chronic HCV genotype 4 patients without cirrhosis.
To demonstrate non-inferiority of oral fosfomycin-trometamol compared to oral ciprofloxacin as a step-down treatment for E.coli AF-UTI in women for the cumulative incidence of survival and clinical cure (resolution of symptoms) 6-10 days post-…
In this study we want to assess the hepatic cyst penetration capacity of intravenously administered antibiotics (ciprofloxacin, co-trimoxazole, doxycycline and piperacillin/tazobactam) by comparing blood and cyst fluid concentrations in patients…
The primary objective is to determine whether the exposure to oral ciprofloxacin and amoxicillin is altered in hospitalized non-critically ill, febrile patients in need of IV antibiotics when they are acutely ill and febrile, compared to when they…
The primary objective is to determine the absorption of orally administered antibiotics in patients with SBS, to guide in clinical decision making when faced with catheter related infections.
To compare exposure to ciprofloxacin between patients with impaired renal function (eGFR < 30 ml/min/1.73m2) admitted to a general ward in the AMC or OLVG location Oost receiving the revised reduced doses (test), patients with impaired renal…
The objective of this trial is to establish if adding antibiotic treatment to surgical drainage of perianalabscess results in less perianal fistulas.
PrimaryTo evaluate confirmed ORR of Trastuzumab deruxtecan in human epidermal growth factor receptor 2- (HER2-) mutated NSCLC subjects treated at 5.4 and 6.4 mg/kg doses.Secundary- To evaluate the clinical efficacy of Trastuzumab deruxtecan at 5.4…